Ischemic Optic Neuropathy

Overview

Anterior ischemic optic neuropathy (AION) is a stroke of the optic nerve head: infarction of the short posterior ciliary arteries that supply the anterior optic nerve. It produces sudden, typically painless vision loss with a swollen disc on exam. The most important step in evaluating AION is telling its two forms apart, since they carry different urgency, treatment, and long-term implications:

• Arteritic AION (A-AION): caused by giant cell arteritis, a systemic vasculitis, and a same-day emergency.
• Non-arteritic AION (NAION): an idiopathic vascular event in a structurally predisposed optic nerve, without systemic vasculitis.

Both present with sudden vision loss and disc edema, and both can produce an altitudinal field defect. That overlap makes the ophthalmic exam alone an unreliable way to tell them apart; the diagnosis rests on history, associated symptoms, and targeted lab testing.

Clinical Features

The vision loss in AION, arteritic or non-arteritic, is characteristically altitudinal: it affects the superior or inferior half of the visual field. The short posterior ciliary arteries supply the optic nerve head in a segmental, watershed-type pattern, so an infarct knocks out one vascular territory, and roughly one half of the nerve's fibers, rather than the whole nerve uniformly. This pattern distinguishes AION from the central scotoma typical of optic neuritis, and it's one of the first things to check on visual field testing when AION is suspected.

Arteritic AION (Giant Cell Arteritis)

Arteritic AION is caused by giant cell arteritis (GCA), a systemic granulomatous vasculitis of medium and large arteries that classically affects patients over 50 to 60, with a female predominance. Ask any older patient with sudden vision loss about associated systemic symptoms: scalp tenderness, jaw claudication, headache, proximal myalgia or stiffness consistent with polymyalgia rheumatica, and unintended weight loss. Their presence often tips the diagnosis toward the arteritic form before any lab result returns.

Markedly elevated ESR and CRP are the key laboratory findings and should be checked urgently whenever GCA-related AION is a possibility. A temporal artery biopsy remains the diagnostic gold standard, but treatment never waits for it. High-dose corticosteroid treatment should begin immediately on clinical suspicion, because the fellow eye can be lost within days of delay. This is the defining urgency of arteritic AION: bilateral blindness within days, with steroids started empirically before biopsy confirmation, not after.

Non-Arteritic AION

Non-arteritic AION (NAION) is the most common acute optic neuropathy in adults over 50. Unlike the arteritic form, it involves no systemic vasculitis: it's an idiopathic ischemic event in an optic nerve that is structurally predisposed to it.

The key structural risk factor is the "disc at risk": a small, crowded optic nerve head with little or no physiologic cup, the opposite of the excavated, cupped disc seen in glaucomatous optic nerve damage. A narrow scleral canal leaves less room for the nerve fibers, and this crowding is thought to predispose the nerve head to ischemia and, once infarction occurs, to compartment-syndrome-like swelling that extends the damage. Vascular risk factors commonly seen alongside NAION include hypertension, diabetes, hyperlipidemia, and obstructive sleep apnea, a risk profile broadly similar to other end-organ ischemic disease. No single mechanism explains why the event happens on a particular night in a particular patient.

NAION is typically painless, presents with sudden altitudinal field loss and a swollen disc, and lacks the systemic symptoms and elevated inflammatory markers of the arteritic form. That absence is exactly how the two are told apart clinically. There is no proven treatment that reliably improves visual outcome in NAION; management centers on risk-factor modification (blood pressure, glucose control, addressing sleep apnea) and counseling about the real, though not universal, risk of fellow-eye involvement over time.

Phosphodiesterase-5 inhibitors such as sildenafil and tadalafil carry a reported, though unproven, association with NAION. The proposed mechanism is transient systemic vasodilation that drops perfusion pressure at an already crowded nerve head. A patient recovering from NAION in one eye should be counseled about this risk before resuming the drug, since the fellow eye carries the same anatomic susceptibility.

Related Topics

Continue exploring Neuro-ophthalmology: